Holen Sie sich die Stockscreener-App
3.66
13.31%
0.43
Handel nachbörslich:
3.70
0.04
+1.09%
Schlusskurs vom Vortag:
$3.23
Offen:
$3.25
24-Stunden-Volumen:
877.27K
Relative Volume:
1.31
Marktkapitalisierung:
$226.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-1.9891
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
+25.77%
1M Leistung:
+92.63%
6M Leistung:
+300.00%
1J Leistung:
+12.96%
1-Tages-Spanne:
$3.25
$3.675
1-Wochen-Bereich:
$2.91
$3.8851
52-Wochen-Spanne:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.66 | 200.32M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Will Pyxis Oncology Inc. stock continue upward momentumEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
How risky is Pyxis Oncology Inc. stock nowJuly 2025 Decliners & Breakout Confirmation Alerts - newser.com
Why Pyxis Oncology Inc. stock is a value investor pickIPO Watch & Weekly High Return Opportunities - newser.com
Will Pyxis Oncology Inc. stock deliver better than expected guidanceSwing Trade & Proven Capital Preservation Tips - newser.com
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance
Strategies to average down on Pyxis Oncology Inc.Chart Signals & Reliable Price Action Trade Plans - newser.com
What makes Pyxis Oncology Inc. stock attractive to growth fundsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Yahoo Finance
Pyxis Oncology to Present Translational Data and Key - GlobeNewswire
ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan
Smart tools for monitoring Pyxis Oncology Inc.’s price action2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Can Pyxis Oncology Inc. stock beat analyst upgradesTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Full technical analysis of Pyxis Oncology Inc. stockJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Developing predictive dashboards with Pyxis Oncology Inc. data2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
Pyxis Oncology Gains 70%, Insider Trades Reap Benefit - 富途牛牛
Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Will Pyxis Oncology Inc. see short term momentumVolume Spike & Pattern Based Trade Signal System - newser.com
Is Pyxis Oncology Inc. stock undervalued vs historical averages2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Is Pyxis Oncology Inc. stock a top pick in earnings seasonRate Cut & AI Enhanced Trading Signals - newser.com
Real time pattern detection on Pyxis Oncology Inc. stockMarket Growth Report & Community Consensus Picks - newser.com
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025 - MarketScreener
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com Australia
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Quiver Quantitative
Pyxis Oncology appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - MarketScreener
Volume spikes in Pyxis Oncology Inc. stock – what they mean2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Pyxis Oncology Inc.’s future2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Pyxis Oncology Inc. stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
What to do if you’re stuck in Pyxis Oncology Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - newser.com
Sector ETF performance correlation with Pyxis Oncology Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Pyxis Oncology Inc.July 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.09%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):